E
Elizabeth Ann L. Enninga
Researcher at Mayo Clinic
Publications - 60
Citations - 981
Elizabeth Ann L. Enninga is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Pregnancy. The author has an hindex of 13, co-authored 44 publications receiving 561 citations. Previous affiliations of Elizabeth Ann L. Enninga include University of Minnesota & Marine Biological Laboratory.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review.
Kavita Narang,Elizabeth Ann L. Enninga,Madugodaralalage D. S. K. Gunaratne,Eniola R. Ibirogba,Ayssa Teles Abrao Trad,Amro Elrefaei,Regan N. Theiler,Rodrigo Ruano,Linda M. Szymanski,Rana Chakraborty,Vesna D. Garovic +10 more
TL;DR: In this paper, the authors summarize guidelines for medical/obstetric care and outline future directions for optimization of treatment and preventive strategies for pregnant patients with COVID-19 with the understanding that relevant data are limited and rapidly changing.
Journal ArticleDOI
Fetal sex-based differences in maternal hormones, angiogenic factors, and immune mediators during pregnancy and the postpartum period.
Elizabeth Ann L. Enninga,Wendy K. Nevala,Douglas J. Creedon,Svetomir N. Markovic,Shernan G. Holtan +4 more
TL;DR: It is unknown whether the sex of the fetus differentially alters the maternal immune milieu, potentially contributing to the observed differences.
Journal ArticleDOI
Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011
Elizabeth Ann L. Enninga,Justin C. Moser,Amy L. Weaver,Svetomir N. Markovic,Jerry D. Brewer,Alexey A. Leontovich,Tina J. Hieken,Lynne Shuster,Lisa A. Kottschade,Ariadna Olariu,Aaron S. Mansfield,Roxana S. Dronca +11 more
TL;DR: The data show no differences in survival between men and women with metastatic melanoma, indicating that the influence of sex on survival is limited to early stage disease but not confined to pre or perimenopausal age groups.
Journal ArticleDOI
Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy.
Elizabeth Ann L. Enninga,Susan M. Harrington,Douglas J. Creedon,Rodrigo Ruano,Svetomir N. Markovic,Haidong Dong,Roxana S. Dronca +6 more
TL;DR: Pregnancy requires balance between tolerance to the haploidentical fetus and the mother's ability to mount immune responses, and soluble program death ligand‐1 soluble PD‐L1 and galectin‐9 in the blood of pregnant women during gestation as these molecules are highly involved in immune suppression during cancer.
Journal ArticleDOI
Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
Narjust Duma,Azzouqa Abdel‐Ghani,Siddhartha Yadav,Katherine P. Hoversten,Clay T Reed,Andrea N. Sitek,Elizabeth Ann L. Enninga,Jonas Paludo,Jesus Vera Aguilera,Konstantinos Leventakos,Yanyan Lou,Lisa A. Kottschade,Haidong Dong,Aaron S. Mansfield,Rami Manochakian,Alex A. Adjei,Roxana S. Dronca +16 more
TL;DR: The results of this study suggest that women may be at a higher risk for immune-related adverse events (irAEs) compared with men when treated with anti-programmed cell death protein 1 therapy.